Attovia Therapeutics announced positive 12-week Phase 1b results for ATTO-1310, showing rapid and sustained itch relief in patients with chronic pruritus and high-itch atopic dermatitis. The company plans to start global Phase 2 trials for ATTO-1310 in the first half of 2027 and expects to initiate Phase 1 trials for ATTO-2306 and ATTO-1091 in the same period. With $395.9 million in cash and equivalents as of September 30, 2026, Attovia expects to fund operations into 2030, positioning itself for multiple clinical milestones ahead.
Attovia Therapeutics shares context is provided here for readers following biotech developments. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 10, 2026 04:11 WIB: Out of 150 priced US health stocks, 125 rose and 23 fell today. Notable movers include DNA at USD 12.41 with a 9.92% increase and 100% buy order activity, Summit Therapeutics (SMMT) at USD 17.90 up 9.61%, and Cassava Sciences (FLNA) at USD 0.50 rising 9.52% but with 88% sell order activity.
AmpliTech Group, a company specializing in RF and microwave components for telecom and defense, will announce its third quarter 2026 financial results on November 12, 2026, after market close. The company will host a conference call at 5:00 PM ET the...
Toll Brothers has announced the grand opening of new luxury single-story model homes at Hidden Vista, a gated community in Palm Desert, California, on November 14. These homes offer up to 2,700 sq ft with 3-4 bedrooms, modern open floor plans, and pr...
FocusReactive, a web development agency specializing in Next.js and headless CMS, achieved top rankings across six major industry review platforms in 2026, including Clutch, DesignRush, and The Manifest. The agency was recognized globally for experti...
Indonesia's e-commerce market is projected to grow from $120.2 billion in 2027 to $239.4 billion by 2032, with a CAGR of 14.78%. Growth is fueled by rising mobile commerce adoption, live-stream shopping, digital payment solutions like PayLater, and e...
Security National Financial Corporation reported a 38.6% drop in after-tax earnings for Q3 2026, falling to $6.17 million due to challenging mortgage market conditions and increased interest rates. The mortgage segment faced a $2.65 million loss driv...
